Geron Company Profile (NASDAQ:GERN)

About Geron (NASDAQ:GERN)

Geron logoGeron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:GERN
  • CUSIP: 37416310
  • Web:
  • Market Cap: $491.85 million
  • Outstanding Shares: 159,176,000
Average Prices:
  • 50 Day Moving Avg: $2.56
  • 200 Day Moving Avg: $2.23
  • 52 Week Range: $1.81 - $3.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 309.00
  • P/E Growth: -2.95
Sales & Book Value:
  • Annual Revenue: $5.95 million
  • Price / Sales: 82.66
  • Book Value: $0.74 per share
  • Price / Book: 4.18
  • EBIDTA: ($28,980,000.00)
  • Net Margins: -469.51%
  • Return on Equity: -21.96%
  • Return on Assets: -20.88%
  • Current Ratio: 15.74%
  • Quick Ratio: 15.74%
  • Average Volume: 1.94 million shs.
  • Beta: 2.82
  • Short Ratio: 22.82

Frequently Asked Questions for Geron (NASDAQ:GERN)

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) released its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.05) EPS for the quarter, hitting analysts' consensus estimates of ($0.05). The company had revenue of $0.54 million for the quarter, compared to the consensus estimate of $0.27 million. Geron had a negative return on equity of 21.96% and a negative net margin of 469.51%. The company's quarterly revenue was down 28.0% compared to the same quarter last year. During the same period last year, the business posted ($0.06) EPS. View Geron's Earnings History.

Where is Geron's stock going? Where will Geron's stock price be in 2017?

5 analysts have issued 12 month price objectives for Geron's shares. Their forecasts range from $2.50 to $5.00. On average, they expect Geron's share price to reach $4.17 in the next year. View Analyst Ratings for Geron.

Are investors shorting Geron?

Geron saw a increase in short interest in April. As of April 28th, there was short interest totalling 33,604,098 shares, an increase of 4.6% from the April 13th total of 32,113,125 shares. Based on an average daily trading volume, of 1,873,067 shares, the days-to-cover ratio is presently 17.9 days. Approximately 21.2% of the company's stock are sold short.

Who are some of Geron's key competitors?

Who owns Geron stock?

Geron's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.90%), Vanguard Group Inc. (4.47%), Geode Capital Management LLC (0.76%), State of New Jersey Common Pension Fund D (0.55%), Bank of New York Mellon Corp (0.49%) and TIAA CREF Investment Management LLC (0.25%). View Institutional Ownership Trends for Geron.

Who sold Geron stock? Who is selling Geron stock?

Geron's stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, NJ State Employees Deferred Compensation Plan, UBS Group AG, TIAA CREF Investment Management LLC, Goldman Sachs Group Inc., ProShare Advisors LLC, Alliancebernstein L.P. and Janney Montgomery Scott LLC. View Insider Buying and Selling for Geron.

Who bought Geron stock? Who is buying Geron stock?

Geron's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, Geode Capital Management LLC, KCG Holdings Inc., Credit Suisse AG, Dimensional Fund Advisors LP, UBS Asset Management Americas Inc. and Creative Planning. View Insider Buying and Selling for Geron.

How do I buy Geron stock?

Shares of Geron can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Geron stock cost?

One share of Geron stock can currently be purchased for approximately $3.09.

Analyst Ratings

Consensus Ratings for Geron (NASDAQ:GERN) (?)
Ratings Breakdown: 3 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $4.17 (34.84% upside)

Analysts' Ratings History for Geron (NASDAQ:GERN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/12/2017Stifel NicolausReiterated RatingHold$2.50LowView Rating Details
4/12/2017Piper Jaffray CompaniesReiterated RatingOverweight$5.00LowView Rating Details
4/6/2017FBR & CoReiterated RatingBuyLowView Rating Details
3/2/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
9/20/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
12/17/2015Janney Montgomery ScottInitiated CoverageBuy$6.50N/AView Rating Details
12/7/2015Oppenheimer Holdings Inc.Reiterated RatingBuy$5.50N/AView Rating Details
8/10/2015MLV & Co.Reiterated RatingBuy$6.00N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for Geron (NASDAQ:GERN)
Earnings by Quarter for Geron (NASDAQ:GERN)
Earnings History by Quarter for Geron (NASDAQ:GERN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.05)($0.05)$0.27 million$0.54 millionViewN/AView Earnings Details
3/1/2017Q416($0.06)($0.05)$0.18 million$0.09 millionViewListenView Earnings Details
11/3/2016Q316($0.06)($0.02)$0.22 million$5.10 millionViewListenView Earnings Details
8/3/2016Q216($0.07)($0.05)$0.38 million$0.21 millionViewListenView Earnings Details
5/5/2016Q116($0.06)($0.06)$0.26 million$0.74 millionViewListenView Earnings Details
2/25/2016Q415($0.05)($0.05)$0.32 million$0.22 millionViewListenView Earnings Details
11/5/2015Q315$0.11$0.17$17.87 million$35.40 millionViewListenView Earnings Details
8/5/2015Q2 15($0.06)($0.05)$0.40 million$0.25 millionViewN/AView Earnings Details
4/30/2015Q1($0.06)($0.06)$0.32 million$0.54 millionViewN/AView Earnings Details
3/3/2015Q4$0.17($0.06)$35.35 million$0.18 millionViewListenView Earnings Details
11/5/2014Q314($0.06)($0.06)$0.28 million$0.16 millionViewN/AView Earnings Details
8/11/2014Q214($0.06)($0.06)$0.22 million$0.34 millionViewListenView Earnings Details
5/1/2014Q114($0.06)($0.06)$0.35 million$0.47 millionViewListenView Earnings Details
3/27/2014($0.06)($0.07)ViewN/AView Earnings Details
3/17/2014Q413($0.07)($0.07)$0.35 millionViewListenView Earnings Details
11/7/2013Q313($0.06)($0.06)$0.49 million$0.18 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.07)($0.07)$0.50 million$0.11 millionViewListenView Earnings Details
4/25/2013Q1 2013($0.08)($0.09)$0.71 million$0.77 millionViewListenView Earnings Details
3/12/2013Q4 2012($0.14)($0.12)$0.50 million$0.69 millionViewListenView Earnings Details
10/30/2012Q312($0.14)($0.13)$0.38 million$0.64 millionViewN/AView Earnings Details
7/31/2012($0.15)($0.14)ViewN/AView Earnings Details
5/2/2012($0.18)($0.15)ViewN/AView Earnings Details
11/3/2011($0.18)($0.16)ViewN/AView Earnings Details
7/28/2011($0.18)($0.17)ViewN/AView Earnings Details
4/27/2011($0.19)($0.20)ViewN/AView Earnings Details
2/24/2011($0.19)($0.39)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Geron (NASDAQ:GERN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.06)($0.06)($0.06)
Q3 20171($0.06)($0.06)($0.06)
Q4 20171($0.06)($0.06)($0.06)
(Data provided by Zacks Investment Research)


Dividend History for Geron (NASDAQ:GERN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Geron (NASDAQ:GERN)
Insider Ownership Percentage: 5.82%
Institutional Ownership Percentage: 37.66%
Insider Trades by Quarter for Geron (NASDAQ:GERN)
Institutional Ownership by Quarter for Geron (NASDAQ:GERN)
Insider Trades by Quarter for Geron (NASDAQ:GERN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/29/2015Olivia Kyusuk BloomCFOSell2,380$3.84$9,139.20View SEC Filing  
3/18/2015Thomas HofstaetterDirectorSell70,000$4.10$287,000.00View SEC Filing  
5/29/2014Melissa Kelly BehrsEVPSell4,826$2.10$10,134.60View SEC Filing  
5/29/2014Olivia Kyusuk BloomCFOSell3,379$2.10$7,095.90View SEC Filing  
5/9/2014Daniel BradburyDirectorBuy142,776$1.75$249,858.00View SEC Filing  
4/1/2014Melissa Kelly BehrsEVPSell12,310$2.13$26,220.30View SEC Filing  
4/1/2014Olivia Kyusuk BloomCFOSell7,435$2.13$15,836.55View SEC Filing  
4/1/2013John A ScarlettCEOBuy50,000$1.03$51,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Geron (NASDAQ:GERN)
Latest Headlines for Geron (NASDAQ:GERN)
DateHeadline logoGeron Corp (GERN) Worth a Look: Stock Adds 7% in Session - May 15 at 11:22 AM logoGeron Co. (GERN) Sees Large Growth in Short Interest - May 12 at 7:00 AM logoGeron reports 1Q loss - May 10 at 10:57 AM logoGeron Co. (GERN) Announces Earnings Results - May 10 at 12:36 AM logoGeron Corporation Reports First Quarter 2017 Financial Results and Recent Events - May 9 at 5:15 PM logoGeron Co. (GERN) Receives Consensus Recommendation of "Hold" from Analysts - May 8 at 4:37 PM logoThis Major Catalyst Sent Geron Corporation Shares Higher by 13% in April - May 3 at 4:17 PM logoZacks Investment Research Lowers Geron Co. (GERN) to Hold - May 2 at 2:28 PM logoFaruqi & Faruqi, LLP Announces a Proposed Class Action Settlement Involving All Persons who Purchased or Acquired Geron Common Stock between December 10, 2012 and March 11, 2014 - May 1 at 11:33 AM logoGeron (GERN) Receiving Somewhat Favorable Press Coverage, Analysis Shows - April 28 at 1:02 AM logoGeron 2017 Annual Meeting of Stockholders to be Held on May 9 - April 25 at 11:13 AM logoPositive Media Coverage Unlikely to Impact Geron (GERN) Share Price - April 22 at 2:51 PM logoSomewhat Positive Media Coverage Somewhat Likely to Impact Geron (GERN) Stock Price - April 18 at 7:13 PM logoGeron Co. (GERN) Receives "Hold" Rating from Stifel Nicolaus - April 14 at 11:00 AM logoPiper Jaffray Companies Reiterates "Overweight" Rating for Geron Co. (GERN) - April 14 at 11:00 AM logoGeron Co. (GERN) Given Average Recommendation of "Hold" by Analysts - April 12 at 8:17 AM logoGeron Corp (GERN) Reports Completion of 2nd Internal Data Review for Imetelstat Trials - April 11 at 12:18 PM logoToday's Research Reports on Biotech Stocks to Watch: Cytori Therapeutics and Geron - April 11 at 12:18 PM logoGeron settling class-action securities suit for $6.25M - April 10 at 7:25 PM logoBUZZ-U.S. STOCKS ON THE MOVE- Axovant, Swift Transportation, Intrawest Resorts, Geron, OncoMed - Nasdaq - April 10 at 5:10 PM logoGeron’s Imetelstat Reports Positive Interim Data - April 10 at 5:10 PM logoAKRX Confirms Acquisition Talks, CBIO Plunges, Be All Ears For GERN - April 10 at 11:26 AM logoGeron Announces Completion of Second Internal Data Reviews for Imetelstat Trials Being Conducted by Janssen - April 10 at 11:26 AM logoGeron completes second internal data reviews for Imetelstat trials; shares ahead 16% premarket - April 10 at 8:49 AM logoGeron Announces Conference Call on April 10 at 8:00 A.M. Eastern Time - April 9 at 10:56 AM logoGeron Co. (GERN) Given Buy Rating at FBR & Co - April 7 at 10:06 PM logoETFs with exposure to Geron Corp. : April 7, 2017 - April 7 at 5:17 PM logoGeron Reports Imetelstat Presentation at American Association for Cancer Research Annual Meeting - April 7 at 10:00 AM logoGeron Corp. breached its 50 day moving average in a Bearish Manner : GERN-US : April 6, 2017 - April 7 at 10:00 AM logoToday's Research Reports on Stocks to Watch: Geron and Galena Biopharma - March 20 at 7:19 PM logoGERON CORP Financials - March 7 at 5:10 PM logoGERON CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits - March 3 at 5:24 PM logoEdited Transcript of GERN earnings conference call or presentation 1-Mar-17 9:30pm GMT - March 3 at 5:24 PM logoGeron reports 4Q loss - March 2 at 10:43 AM logoGeron (GERN) Q4 Loss Narrows; Focus Remains on Imetelstat - March 2 at 10:43 AM logo4:08 pm Geron reports EPS in-line, misses on revs - March 2 at 10:43 AM logoGeron Announces Presentation at American Association for Cancer Research Annual Meeting - March 2 at 10:43 AM logoGeron Corporation's (GERN) CEO John Scarlett on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha - March 1 at 10:06 PM logoEARNINGS SUMMARY: Details of Geron Corporation Q4 Earnings Report - March 1 at 5:04 PM logoGERON CORP Files SEC form 10-K, Annual Report - March 1 at 5:04 PM logoGeron Corporation Reports Fourth Quarter and Annual 2016 Financial Results - March 1 at 5:04 PM logoGERON CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 1 at 5:04 PM logoGeron Corp Earnings Call scheduled for 4:30 pm ET today - March 1 at 5:04 PM logoQ4 2016 Geron Corp Earnings Release - After Market Close - March 1 at 12:18 PM logoDrug Stocks Q4 Earnings Lineup for Mar 1: MYL, KERX & More - February 28 at 8:48 AM logoGeron Announces Conference Call to Discuss Fourth Quarter and Annual 2016 Financial Results - February 22 at 11:52 AM logoGeron (GERN) Q4 Earnings: What's in Store for the Stock? - February 17 at 8:54 AM logoGERON CORP Files SEC form 8-K, Change in Directors or Principal Officers - February 10 at 6:02 PM



Geron (GERN) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff